A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...

Objective: To characterize and further compare the immune cell populations of the tumor microenvironment (TME) in both clear cell and papillary renal cell carcinoma (RCC ... tissues derived from the ...

Hypocalcemia may result from deficient calcium intake, vitamin D deficiency, steatorrhea, acute pancreatitis, renal disease ... of the kidney at autopsy were within normal limits.

Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification of RCC is primarily based on distinct morphological and molecular ...

Clear cell renal cell carcinoma (ccRCC ... antiprogrammed cell PD-1 IgG4k antibody that has been approved in China for the treatment of kidney carcinoma. The utilization of ICIs has shown significant ...